Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Seeking Alpha

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Progress on OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and new data from Phase 1/2 Preliminary safety and efficacy update on OCU410 Phase 1/2 ArMaDa clinical trial for ...
Ophthalmology Times

PRIMA retinal implant restores vision in patients with advanced GA

An editorial published in the New England Journal of Medicine 1 referred to the Photovoltaic Retina Implant Microarray (PRIMA ...

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...
Nasdaq

Ocugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400

Ocugen reported clinical trial progress and financial results, highlighting advancements in gene therapies for retinal diseases and recent FDA alignments. OCU410ST is a therapy for Stargardt disease, ...
Business Wire

Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy (GA) Clinical Trial

Phase 1 investigator-sponsored clinical trial “Evaluation of Kamuvudine-8 in Subjects with Geographic Atrophy (K8 for GA)” for a blinding condition resulting from dry age-related macular degeneration ...
Nasdaq

Ocugen, Inc. Reports Favorable Safety and Tolerability Data for OCU410 in Phase 1/2 Clinical Trial for Geographic Atrophy

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA) ...